KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occu…
Molecular profiling of the tumour immune microenvironment (TIME) has enabled the rational choice of immunotherapies in some adult cancers. In contras…
Cancer continues to be a leading cause of death globally. However, there remains a significant disparity in the reported incidence of cancer in devel…
Dysphagia, one of the most common complications in head and neck cancer (HNC) treated with radiotherapy, can severely affect patients’ quality of lif…
The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.
Associate Professor Lesterhuis said the gel, developed with the help of chemists at The University of Western Australia, could revolutionise the way…
The Kids Research Institute Australia is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for on…
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) consists of EGFR, ErbB2, ErbB3, and ErbB4. These receptors pla…
Researchers have identified key differences between cancers that respond to immunotherapy and those that do not.
Researchers at The Kids Research Institute Australia and UWA will use a $500,000 CUREator grant to progress the development of the first cancer immun…